RESEARCH TRIANGLE, N.C., July 30, 2026
Basking Biosciences has announced the publication of groundbreaking preclinical research in Communications Biology, a Nature Portfolio journal, demonstrating that its lead investigational therapy BB-031 successfully restored blood flow in a microfluidic model of Acute Ischemic Stroke (AIS) using blood samples from stroke patients. The findings highlight the therapeutic potential of BB-031, a first-in-class, targeted, reversible thrombolytic therapy that selectively inhibits von Willebrand Factor (vWF), a key protein involved in blood clot formation and stabilization. Conducted by researchers at the University of Pittsburgh and The Ohio State University, the study demonstrated that BB-031 outperformed currently approved thrombolytic therapies, alteplase (tPA) and tenecteplase (TNK), particularly against mature platelet-rich clots that are often resistant to existing treatments. The publication strengthens scientific support for the company’s ongoing Phase 2 RAISE clinical trial, which is evaluating BB-031 in patients with acute ischemic stroke.
BB-031 Demonstrates Superior Blood Flow Restoration in Stroke Model
The published study evaluated BB-031 using an advanced microfluidic arterial occlusion model that closely mimics human stroke conditions by generating platelet-rich clots under physiological arterial blood flow. Researchers found that BB-031 restored blood flow more effectively than both alteplase and tenecteplase, including clots that had matured for three to six hours, a stage where current fibrinolytic therapies often show reduced effectiveness. Unlike conventional clot-dissolving drugs, BB-031 selectively targets von Willebrand Factor (vWF), preventing it from continuously recruiting new platelets that reinforce clot stability and resistance to treatment. Blood samples obtained from acute ischemic stroke patients further confirmed the therapy’s ability to restore circulation while accurately reproducing clot composition observed in patients undergoing endovascular thrombectomy (EVT). These findings provide valuable mechanistic evidence supporting BB-031 as a promising next-generation thrombolytic therapy capable of addressing limitations associated with current standard-of-care treatments.
Novel vWF Inhibition Could Expand Stroke Treatment Opportunities
Acute Ischemic Stroke remains one of the leading causes of death and long-term disability worldwide, with existing pharmacological treatments restricted by a narrow 3- to 4.5-hour therapeutic window and significant bleeding risks. Mechanical thrombectomy has extended treatment opportunities for selected patients but remains available primarily at specialized stroke centers. BB-031 introduces a fundamentally different therapeutic strategy by selectively and reversibly inhibiting von Willebrand Factor, disrupting platelet-mediated clot stabilization while preserving the potential for rapid reversal if bleeding occurs. The investigational therapy is paired with BB-025, a proprietary rapid-acting oligonucleotide reversal agent specifically designed to neutralize BB-031 within minutes, allowing physicians to quickly restore normal blood clotting if emergency surgery or bleeding management becomes necessary. This built-in safety mechanism has the potential to improve physician confidence while expanding treatment eligibility for many patients who currently receive no acute stroke intervention.
Advertisement
Phase 2 Clinical Development Advances Toward Improved Stroke Care
The newly published research provides important scientific validation as Basking Biosciences continues advancing BB-031 through its Phase 2 RAISE clinical trial, a multicenter, randomized, double-blind, dose-finding study comparing the investigational therapy against placebo in patients presenting with acute ischemic stroke within 24 hours of symptom onset. Following the successful completion of Part A in 2025, the ongoing Part B is expected to enroll approximately 180 patients across clinical sites in North America and Australia, with additional sites planned. The company believes the combination of BB-031’s targeted thrombolytic activity and BB-025’s rapid reversal capability could significantly broaden treatment access while improving safety and effectiveness compared with existing stroke therapies. As stroke continues to affect millions of patients globally each year, these encouraging preclinical findings reinforce the potential of next-generation targeted therapies to transform acute stroke management and improve long-term patient outcomes.
Source: Basking Biosciences press release
